BiotechTube

canakinumab + dexamethasone

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Arthritis, Gouty

Conditions

Arthritis, Gouty

Trial Timeline

Apr 1, 2008 → Oct 1, 2009

NCT ID
NCT00663169

About canakinumab + dexamethasone

canakinumab + dexamethasone is a phase 2 stage product being developed by Novartis for Arthritis, Gouty. The current trial status is completed. This product is registered under clinical trial identifier NCT00663169. Target conditions include Arthritis, Gouty.

What happened to similar drugs?

20 of 20 similar drugs in Arthritis, Gouty were approved

Approved (20) Terminated (0) Active (0)
✅NISEDr. Reddy's LaboratoriesApproved
✅Duloxetine + Sugar pillEli LillyApproved
✅Baricitinib + TNF InhibitorEli LillyApproved
✅Ixekizumab + AdalimumabEli LillyApproved
✅TacrolimusAstellas PharmaApproved
✅tacrolimus + methotrexate + adalimumab + tocilizumab + abataceptAstellas PharmaApproved
✅tacrolimus + placeboAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00663169Phase 2Completed

Competing Products

20 competing products in Arthritis, Gouty

See all competitors
ProductCompanyStageHype Score
DRL_RI + Rituxan + MabTheraDr. Reddy's LaboratoriesPhase 1/2
29
Experimental: Arm A: DRL_RI + Arm B: Rituxan®/Mabthera®Dr. Reddy's LaboratoriesPhase 3
37
NISEDr. Reddy's LaboratoriesApproved
40
NISELATDr. Reddy's LaboratoriesPre-clinical
23
Test Product + Reference product + Reference Medicinal ProductDr. Reddy's LaboratoriesPhase 1
22
Tocilizumab Prefilled SyringeDr. Reddy's LaboratoriesPhase 1
26
TilmanoceptNavidea BiopharmaceuticalsPhase 1
11
Tc99m tilmanoceptNavidea BiopharmaceuticalsPhase 2
25
KPL-404 + PlaceboKiniksa PharmaceuticalsPhase 2
29
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic AcidEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
LY2828360 + PlaceboEli LillyPhase 2
35
Investigational Medical Product (IMP) administered in parent studyEli LillyPhase 3
40
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
Sonelokimab + Placebo + AdalimumabMoonLake ImmunotherapeuticsPhase 2
29
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab + Placebo + RisankizumabMoonLake ImmunotherapeuticsPhase 3
41
Dose A VTX958 + Dose B VTX958 + PlaceboVentyx BiosciencesPhase 2
21
LY2127399Eli LillyPhase 3
32
Ixekizumab + PlaceboEli LillyPhase 3
40